Mainstreaming Cannabinoids - Everything you need to know from regulators, legislators, and scientists
This discussion will shed specific light on the nature of Current Good Manufacturing Practices (CGMPs), which regulate information available on public state-run websites and other sources that document the minimum requirements for the methods, facilities, and controls used in manufacturing, processing, and packaging of a drug product to assure it is safe for use. The conversation will focus on the fact that these same standards should be applicable to medical cannabis products presently in development that may be sold in the United States and will amplify the study and the need for standardized testing protocols and methodologies to ensure consumer safety.
Other Resources / Information
- Better communication between the FDA and CGMPs is crucial to developing federal regulations to consumer health and safety for cannabis use products.
- Standard practices are presently in place for most FDA-approved F&B products. The same set of rules should apply to products that include cannabinoid
- Standardized testing protocols and methodologies are critical in order to ensure consumer safety. The FDA can make this happen
- Sarah Chase, Executive Director, Council for Federal Cannabis Regulation
- Steve Winter, President, Brotman|Winter|Fried Communications
Steve Winter, President, Brotman|Winter|Fried Communications
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.